DJ A.I. in New Drug Discovery and Development Takes Center Stage at New York Health Forum (226330.KQ) Syntekabio Inc. A.I. in New Drug Discovery and Development Takes Center Stage at New York Health
Enzychem Lifesciences Announces Database Lock for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Enzychem Lifesciences to Present at BIO Digital 2021
News provided by
Share this article
Share this article
ENGLEWOOD CLIFFS, N.J., May 25, 2021 /PRNewswire/ Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biopharmaceutical company developing innovative medicines to improve the lives of patients with cancer and inflammatory diseases, announced that the company will present at BIO Digital 2021, held virtually June 10-17, 2021.
Enzychem s lead investigational compound, EC-18 is an immunomodulator which accelerates the pattern recognition receptors (PRRs) and shortens the duration of inflammatory immune response by quickly removing PAMP/DAMP associated danger signals. We look forward to meeting investors and potential partners at BIO Digital, as we will be announcing Phase 2 data for our lead clinical asset EC-18 in chemoradiation-induced oral mucositis in 3Q 2021, said Dohyun Cho, Ph.D., Chief Operating Officer, Enzychem Lifesciences. Our programs in COVID-19
Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program
News provided by
Share this article
Share this article
ENGLEWOOD CLIFFS, N.J., April 20, 2021 /PRNewswire/ Enzychem Lifesciences (KOSDAQ: 183490), a biopharmaceutical company developing innovative medicines to improve the lives of patients with cancer and inflammatory diseases, today announced that it has been selected to collaborate with the Chemical Countermeasures Research Program (CCRP) at the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), the Biomedical Advanced Research and Development Authority (BARDA) under the Department of Health and Human Services, and Battelle to evaluate the therapeutic efficacy of EC-18 as a medical countermeasure (MCM) for inhalation Sulfur Mustard exposure.
Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.